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 Chagas disease remains an important health problem in South, Central and some parts 
of North America. It is caused by infection with the protozoa Trypansoma cruzi and the 
disease has an initial acute phase followed by chronic infection in the absence of appropriate 
treatment [1;2]. In the chronic phase of the disease 20-30% of patients can develop a 
cardiomyopathy [1;2]. It is generally thought that the Trypansoma cruzi parasite is able to 
evade immune clearance. This leads to a chronic inflammatory response within the 
myocardium characterised by infiltration of various T-cell subtypes and release of 
inflammatory mediators including IL-18, TNF- and TGF-.  The latter is thought to be a 
key driver of the inflammatory and fibrotic response [2]. The development of the cardiac 
disease is highly variable but at its’ worse it can result in a disease resembling dilated 
cardiomyopathy with ventricular aneurysms and severe heart failure [1;2]. Cardiac 
arrhythmias are a prominent feature of the disease and include bradycardia, heart block, atrial 
fibrillation, bundle branch block, ventricular ectopics and malignant ventricular arrhythmias 
leading to sudden cardiac death [1;2]. 
 In this issue of the journal, Medei and colleagues look at a specific feature in the 
pathogenesis of the arrhythmic diathesis. The authors have previously described an 
interesting feature of the immune response in Chagas cardiomyopathy patients namely the 
production of autoantibodies particularly to the  adrenergic receptor [3]. The presence of 
autoantibodies correlated with the risk of arrhythmia occurrence in patients. However in 
normal rabbit hearts addition of the patient sera did not lead to the induction of arrhythmia 
and only modest electrophysiological abnormalities [3].  The current paper now extends this 
work. They use a well-established pharmacological model of hereditary long QT syndrome 
(LQTS2) in which isolated rabbit hearts are treated with E-4031 which is a specific inhibitor 
of HERG potassium channels; a key repolarising current [4;5]. In this setting the application 
of the patient antisera led to shortening of the QT interval but increased Tpeak-Tend, a 
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marker of the spatial dispersion of repolarisation. Furthermore, the antisera induced 
ventricular rhythm disturbances including ventricular ectopics, ventricular tachycardia and 
torsade-de-pointes and AV nodal block. Finally, ventricular action potentials were measured 
using sharp microelectrodes in muscle strips and the combination of E-4031 and the patient 
antisera led to early afterdepolarisations. Control antisera did not lead to these effects and the 
effects were reversed by a -blocker.   
 The paper makes a plausible case for a contribution of this mechanism in addition to 
the fibrosis and structural heart disease. Indeed the early afterdepolarisations could precipitate 
re-entry in hearts with significant structural damage. It is known that the QTc interval is 
prolonged in chronic cardiac Chagas disease and thus in the diseased heart this may interact 
with the autoantibodies stimulating the -adrenergic receptor to promote arrhythmia [2]. 
Furthermore, increased adrenergic drive is known to be proarrhythmic in a variety of settings 
including in the long QT syndrome [5]. It also leads to some therapeutic considerations. The 
management of heart failure associated with Chagas cardiomyopathy is very much treated 
along standard lines [2]. -blockers are used and the results of this study support that 
approach. However their use can be complicated by the brady-arrhythmias associated with 
the disease. Patients with the hereditary long QT syndromes are advised to avoid certain 
drugs (http://www.sads.org.uk/drugs-to-avoid/) and where good alternatives exist it may be 
prudent to take this precaution.    
 The paper uses rabbit ex-vivo preparations with the acute addition of patient derived 
sera. In humans with the disease other considerations may be at play in the genesis of the 
arrhythmia. Patients with Chagas disease have a blunting of autonomic control of cardiac 
dysfunction is present [6]. Sympathetic tone probably declines later compared to other causes 
of heart failure [7]. The dysautonomia likely occurs because of the inflammatory process 
damaging nerve termini and plexi in the heart. Furthermore, autoantibodies have been 
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described to muscarinic as well as adrenergic receptors in this disease [3]. In-vivo, the 
chronic production of autoantibodies may rather lead to receptor desensitisation and 
degradation and contribute to the dysautonomia. It is impossible to test this except in some 
kind of animal model of the actual infective disease. However, Medei and colleagues make 
an interesting contribution to the understanding of arrhythmia in Chagas disease emphasising 
how different substrates may interact.      
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